ANZCTR search results

Trial completed with 6 subjects recruited. The breath test was not useful in predicting %FU toxicity. The Thymine test was useful in identifying soem patients with 5FU toxicity.

Epidermal growth factor receptor inhibitors (EGFRIs) have been shown efficacy in the treatment of several cancers but despite their potential to be revolutionary therapeutic agents, they are commonly associated with undesirable skin side effects, some of which are chronic or have profound physical and psychosocial impact on patients. This study aims to assess physiological skin changes in patients on EGFRIs using transepidermal water loss (TEWL), skin pH, skin sebum levels, skin surface hydration and surface perfusion measurements in conjunction with microbiology swabs, clinical photography and the Dermatology Quality of Life Index (DQLI) in order to understand the pathophysiology of cutaneous side effects, better characterise these toxicities using a refined classification system and evaluate subclinical changes before overt disease in order to prevent and minimise cutaneous side effects.

The purpose of this study was to investigate the effectiveness of clinically applied treatment include manual therapy, supervising exercises and electro-acupuncture like TENS compared with well-designed home exercise program for OA of the knee. Our hypothesis was that physical therapy consisting of manual therapy, supervised exercises and electro-acupuncture like TENS (EA like TENS) conducted in the clinic would be more effective than exercise program performed at home for decreasing pain and improving function.

Heart failure is a common, disabling condition. Research has shown that a disease management programme for patients recently in hospital with heart failure, including education, attention to diet, exercise and medications, and regular review by trained staff can reduce death and hospital admissions. There is some evidence to suggest benefits of a supervised programme of exercise in improving fitness and well-being in this patient group. This study will show whether adding regular supervised gym-based exercise to a disease management programme can further improve important outcomes including death, hospital use and depression in a cost-effective manner.

This trial has now been completed and recruited 20 adoelcents with Dwon syndrome who were randomly allocation to either a progressive resistance training intervention group or a wait list control group.

Genital HPV is the necessary cause for cervical cancer, as well as a major contributing cause of several other cancers and conditions. There are now effective vaccines against the main oncogenic HPV types, HPV16 and 18; most research and discussion has focussed around targeting the vaccine to young women and older adolescents. Based on this, a national free HPV vaccination program for adolescent girls will commence in 2007. There is no research on the use of this vaccine in immunosuppressed. Therefore, information on the immunogenicity, safety and duration of efficacy of HPV vaccine when administered to immunosuppressed children is needed.

The main purpose of this research study is to evaluate the antiretroviral (how effective the drug is at reducing the amount of HIV in the blood) activity of two different doses of MPC-4326 in HIV-1 positive participants and what, if any, side effects there may be through 14 days of dosing. This study will also evaluate the antiretroviral activity and safety of bevirimat in participants who continue treatment with bevirimat as part of combination highly active antiretroviral therapy for up to 72 weeks. We also want to know how much of the drug gets into your blood stream following oral administration. We are asking participants who will start their treatment for the first time (so called naïve (exposed to treatment for the first time) participants) and who are already on treatment (treatment experienced participants) to participate. If you choose to participate in this study and do not intend to continue MPC-4326 treatment past 14 days, you should not expect any medical benefits from taking part in this study and it is even possible that your HIV could worsen during the study. The potential benefit to society may be information gained on the safety and effectiveness of the study treatment for patients in the future. However, if you choose to participate in this study and intend to continue MPC-4326 treatment past 14 days should your viral load reduction in those first 14 days be at least two-thirds or 66.6% as compared with your viral load value at baseline, then you may have medical benefits from taking part in this study. These possible benefits include a persistent viral load reduction and an improvement in the CD4 count (a blood marker of immune system health) that may occur. As this is an experimental medication, the likelihood of these benefits occurring for you is not yet known.

This study is a 16 week, double blind, placebo controlled investigation of the effects of a Women’s 50+ multivitamin antioxidant supplement on memory and brain function in women aged 65 to 80 years who are experiencing memory decline. Additionally, this study aims to investigate the possible mechanisms which underlie memory impairment in older adults including cardiovascular risk factors, oxidative stress and brain activity (EEG).

This is a trial of the drug Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in people being treated for germ cell tumours with cisplatin-based chemotherapy. Who is it for? You can join this study if you: - have germ cell cancer that is at early or local, locally advanced or locally recurrent stage - are being treated with cisplatin-based chemotherapy. Trial details All participants receive anti-emetic (anti-vomiting or dry retching) treatment with Aprepitant for seven days while they are receiving their first cycle of Cisplatin-based chemotherapy. The study will measure the number of participants with no emesis during day 1 to 8 of chemotherapy. Chemotherapy-induced nausea and vomiting is an unpleasant side effect of chemotherapy for germ cell tumours, and this study hopes to minimise this.